Form D · Other Technology
Scribe Therapeutics, Inc.
Alameda, CA · CIK 0001853921
Offering snapshot reported Apr 2, 2021 · SEC filing
- Reported sold
- $100M Offering amount: $100M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 17, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 2, 2021 | Initial | $100,000,002 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-394477
Source: Form D, filed Apr 2, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Behzad Aghazadeh | Director |
| Carl Gordon | Director |
| Benjamin Oakes | Director, Executive |
| Vijay Pande | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
1150 Marina Village Pkwy
Alameda, CA, 94501
Alameda, CA, 94501